GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Insulet Corp (NAS:PODD) » Definitions » Operating Margin %
中文

Insulet (Insulet) Operating Margin %

: 20.87% (As of Dec. 2023)
View and export this data going back to 2007. Start your Free Trial

Operating Margin % is calculated as Operating Income divided by its Revenue. Insulet's Operating Income for the three months ended in Dec. 2023 was $106 Mil. Insulet's Revenue for the three months ended in Dec. 2023 was $510 Mil. Therefore, Insulet's Operating Margin % for the quarter that ended in Dec. 2023 was 20.87%.

Good Sign:

Insulet Corp operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Insulet's Operating Margin % or its related term are showing as below:

PODD' s Operating Margin % Range Over the Past 10 Years
Min: -18.47   Med: 3.87   Max: 12.96
Current: 12.96


PODD's Operating Margin % is ranked better than
73.13% of 815 companies
in the Medical Devices & Instruments industry
Industry Median: 1.27 vs PODD: 12.96

Insulet's 5-Year Average Operating Margin % Growth Rate was 9.10% per year.

Insulet's Operating Income for the three months ended in Dec. 2023 was $106 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $220 Mil.


Insulet Operating Margin % Historical Data

The historical data trend for Insulet's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insulet Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.77 5.69 11.47 2.88 12.96

Insulet Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.36 7.74 7.84 12.66 20.87

Competitive Comparison

For the Medical Devices subindustry, Insulet's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insulet Operating Margin % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Insulet's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Insulet's Operating Margin % falls into.



Insulet Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Insulet's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=220 / 1697.1
=12.96 %

Insulet's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=106.4 / 509.8
=20.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Insulet  (NAS:PODD) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Insulet Operating Margin % Related Terms

Thank you for viewing the detailed overview of Insulet's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Insulet (Insulet) Business Description

Traded in Other Exchanges
Address
100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 360,000 insulin-dependent diabetics are using it worldwide.
Executives
Luciana Borio director C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677
Shacey Petrovic officer: CCO 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Prem Singh officer: SVP, Global Operations C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
James Hollingshead director C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123
Wayde D. Mcmillan officer: EVP, CFO C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Mark N Field officer: SVP & Chief Technology Officer C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Dan Manea officer: SVP, Chief HR Officer C/O INSULET CORPORATION, 100 NAGOG PARK, ACTION MA 01720
Michael R Minogue director 22 CHERRY HILL DR, C/O ABIOMED INC, DANVERS MA 01923
Laetitia Cousin officer: SVP, Reg, Quality & Compliance C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Charles Alpuche officer: SVP, Global Manufacturing C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Bret Christensen officer: SVP and CCO 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Michael P Spears officer: SVP, Quality and Regulatory C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Elizabeth H Weatherman director C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
David A Lemoine director C/O THE L S STARRETT COMPANY, 121 CRESCENT STREET, ATHOL MA 01331
Sally Crawford director C/O HOLOGIC, INC., BEDFORD MA 01730

Insulet (Insulet) Headlines

From GuruFocus

Insulet Corp at Nasdaq Investor Conference Transcript

By GuruFocus Research 01-23-2024

Q4 2022 Insulet Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Insulet Corp at Cowen Health Care Conference Transcript

By GuruFocus Research 01-23-2024

Q4 2021 Insulet Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2022 Insulet Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2022 Insulet Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2021 Insulet Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Insulet Corp at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024